Prosecution Insights
Last updated: October 04, 2026
Application No. 18/333,942

CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES

Final Rejection §103§DOUBLEPATENT
Filed
Jun 13, 2023
Priority
May 11, 2015 — EU PCT/EP2015/060357 +2 more
Examiner
SKELDING, ZACHARY S
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
OA Round
2 (Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
498 granted / 834 resolved
At TC average
Strong +41% interview lift
Without
With
+41.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
46 currently pending
Career history
871
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
27.2%
-12.8% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
39.6%
-0.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 834 resolved cases

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendments and remarks filed 8-14-26 are acknowledged. Claims 44-56 and 58-68 are pending and under examination. The prior rejections under 35 USC § 103 have been withdrawn in view of applicant’s claim amendments and argument. In particular, with respect to the first 103 rejection, given (i) the declaration of Dr. Oehm (dated 1-9-23) which was originally filed with the parent application (“the ‘919”), and further given (ii) applicant’s arguments about how the teachings of the WO’327 that were relied upon in the first rejection under 35 USC § 103 “originated with the common inventors,” the undersigned agrees with applicant’s assessment that “the WO’327 application is a disclosure that falls under the exception of AIA 35 U.S.C. § 102(b)(2)(A). With respect to the second 103 rejection, given that claim 57 was not previously rejected, and claim 56 has been amended to include the limitation of claim 57, the second 103 rejection has been obviated. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 44-56 and 58-68 stand rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 11,713,346, essentially for the reasons of record. Applicant does not challenge the merits of the nonstatutory double patenting rejection set forth in the prior Office Action; rather, applicant states that they “…will consider filing a TD once the aforementioned obviousness rejections have been withdrawn.” As set forth above, 44-56 and 58-68 stand rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 11,713,346, essentially for the reasons of record. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY S SKELDING whose telephone number is (571)272-9033. The examiner can normally be reached M-F 9-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ZACHARY S SKELDING/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Jun 13, 2023
Application Filed
Apr 14, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Aug 14, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747300
Methods and Antibody Compositions for Tumor Treatment
4y 2m to grant Granted Sep 29, 2026
Patent 12742017
ANTI-CD36 ANTIBODIES AND USES THEREOF
2y 0m to grant Granted Sep 22, 2026
Patent 12715919
ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY
3y 4m to grant Granted Aug 25, 2026
Patent 12698340
COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF SOLID TUMORS
5y 4m to grant Granted Aug 04, 2026
Patent 12698331
NEW ANTIBODY BLOCKING HUMAN FCGRIIIA AND FCGRIIIB
4y 1m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+41.2%)
3y 7m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 834 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month